董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Panzara | 男 | Director | 59 | 5.92万美元 | 0.72 | 2026-03-24 |
| Joseph Edelman | 男 | Director | 70 | 4.92万美元 | 186.80 | 2026-03-24 |
| Kelly A. Romano | 女 | Chairwoman of the Board | 64 | 9.07万美元 | 1.64 | 2026-03-24 |
| Mark Litton | 男 | President, Chief Executive Officer and Director | 58 | 142.38万美元 | 24.55 | 2026-03-24 |
| Barbara Kosacz | 女 | Director | 68 | 5.92万美元 | 0.83 | 2026-03-24 |
| Grant Pickering | 男 | Director | 58 | 5.02万美元 | 0.99 | 2026-03-24 |
| Kelly A. Romano | 女 | Chairwoman of the Board | 64 | 未披露 | 未持股 | 2026-03-24 |
| John M. Fluke, Jr. | 男 | Director | 83 | 5.27万美元 | 2.46 | 2026-03-24 |
| James A. Johnson | 男 | Director | 69 | 7.02万美元 | 1.02 | 2026-03-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Litton | 男 | President, Chief Executive Officer and Director | 58 | 142.38万美元 | 24.55 | 2026-03-24 |
| Kevin Church | 男 | Chief Scientific Officer | 41 | 133.61万美元 | 未持股 | 2026-03-24 |
| Javier San Martin | 男 | Chief Medical Officer | 60 | 81.01万美元 | 5.36 | 2026-03-24 |
| Mark Worthington | 男 | Chief Compliance Officer and Corporate Secretary and General Counsel | 59 | 73.15万美元 | 8.93 | 2026-03-24 |
| Robert Renninger | 男 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2026-03-24 |
| Robert Renninger | 男 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2026-03-24 |
董事简历
中英对照 | 中文 | 英文- Michael Panzara
-
Michael Panzara自2020年5月起担任Wave Life Sciences Ltd.首席医疗官、治疗发现和开发主管。在2018年11月至2020年4月期间，Panzara博士担任Wave Life Sciences Ltd.首席医疗官。在2016年7月至2018年10月期间，Panzara博士担任Wave Life Sciences Ltd.神经病学特许经营主管。在加入Wave Life Sciences Ltd.之前，Panzara博士曾在Sanofi Genzyme和 Genzyme Corporation担任过各种职务，Genzyme Corporation于2011年与赛诺菲合并，从2009年到2016年7月，最近担任多发性硬化症负责人，神经病学和眼科治疗领域的全球发展，在此之前，担任集团副总裁，治疗领域负责人，多发性硬化症和神经病学。在加入Genzyme之前，Panzara博士在Biogen担任过越来越多的职责，包括2006年至2009年担任神经病学副总裁、首席医疗官，以及2001年至2006年在医学研究组担任过各种职务。此外，从1999年到2011年，Panzara博士是哈佛医学院神经病学讲师和马萨诸塞州总医院神经病学助理。他于1994年至1998年在MGH接受神经病学培训，并在布莱根妇女医院完成了免疫学和风湿病学的博士后培训。Panzara博士拥有宾夕法尼亚大学学士学位、斯坦福大学医学院医学学位和哈佛大学公共卫生学院公共卫生硕士学位。
Michael Panzara has served as Wave Life Sciences Ltd. Chief Medical Officer, Head of Therapeutics Discovery and Development since May 2020. During the period of November 2018 through April 2020 Dr. Panzara served as Wave Life Sciences Ltd. Chief Medical Officer. During the period of July 2016 to October 2018 Dr. Panzara served as Wave Life Sciences Ltd. Franchise Lead, Neurology. Prior to joining Wave Life Sciences Ltd., Dr. Panzara served in various roles at Sanofi Genzyme and Genzyme Corporation before its merger with Sanofi in 2011 from 2009 to July 2016 most recently serving as Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development and prior to that, serving as Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology. Prior to joining Genzyme, Dr. Panzara served in roles of increasing responsibility at Biogen, including Vice President, Chief Medical Officer, Neurology from 2006 to 2009 and in various roles in the Medical Research group from 2001 to 2006. In addition, from 1999 to 2011 Dr. Panzara was an Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at Massachusetts General Hospital (MGH). He trained in neurology at MGH from 1994 to 1998 and completed his post-doctoral training in immunology and rheumatology at Brigham and Women's Hospital. Dr. Panzara holds a bachelor's degree from the University of Pennsylvania, a medical degree from Stanford University School of Medicine, and a master's degree in public health from the Harvard School of Public Health. - Michael Panzara自2020年5月起担任Wave Life Sciences Ltd.首席医疗官、治疗发现和开发主管。在2018年11月至2020年4月期间，Panzara博士担任Wave Life Sciences Ltd.首席医疗官。在2016年7月至2018年10月期间，Panzara博士担任Wave Life Sciences Ltd.神经病学特许经营主管。在加入Wave Life Sciences Ltd.之前，Panzara博士曾在Sanofi Genzyme和 Genzyme Corporation担任过各种职务，Genzyme Corporation于2011年与赛诺菲合并，从2009年到2016年7月，最近担任多发性硬化症负责人，神经病学和眼科治疗领域的全球发展，在此之前，担任集团副总裁，治疗领域负责人，多发性硬化症和神经病学。在加入Genzyme之前，Panzara博士在Biogen担任过越来越多的职责，包括2006年至2009年担任神经病学副总裁、首席医疗官，以及2001年至2006年在医学研究组担任过各种职务。此外，从1999年到2011年，Panzara博士是哈佛医学院神经病学讲师和马萨诸塞州总医院神经病学助理。他于1994年至1998年在MGH接受神经病学培训，并在布莱根妇女医院完成了免疫学和风湿病学的博士后培训。Panzara博士拥有宾夕法尼亚大学学士学位、斯坦福大学医学院医学学位和哈佛大学公共卫生学院公共卫生硕士学位。
- Michael Panzara has served as Wave Life Sciences Ltd. Chief Medical Officer, Head of Therapeutics Discovery and Development since May 2020. During the period of November 2018 through April 2020 Dr. Panzara served as Wave Life Sciences Ltd. Chief Medical Officer. During the period of July 2016 to October 2018 Dr. Panzara served as Wave Life Sciences Ltd. Franchise Lead, Neurology. Prior to joining Wave Life Sciences Ltd., Dr. Panzara served in various roles at Sanofi Genzyme and Genzyme Corporation before its merger with Sanofi in 2011 from 2009 to July 2016 most recently serving as Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development and prior to that, serving as Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology. Prior to joining Genzyme, Dr. Panzara served in roles of increasing responsibility at Biogen, including Vice President, Chief Medical Officer, Neurology from 2006 to 2009 and in various roles in the Medical Research group from 2001 to 2006. In addition, from 1999 to 2011 Dr. Panzara was an Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at Massachusetts General Hospital (MGH). He trained in neurology at MGH from 1994 to 1998 and completed his post-doctoral training in immunology and rheumatology at Brigham and Women's Hospital. Dr. Panzara holds a bachelor's degree from the University of Pennsylvania, a medical degree from Stanford University School of Medicine, and a master's degree in public health from the Harvard School of Public Health.
- Joseph Edelman
-
Joseph Edelman担任我们的董事会主席。Edelman先生是Perceptive Advisors的创始人，首席执行官和投资组合经理。自2020年7月起，他还担任Arya Sciences Acquisition Corp Iii（Nasdaq:ARYA）的董事会主席。创立Perceptive Advisors之前，Edelman从1994年到1998年担任Aries Fund（Paramount Capital Asset Management生物技术对冲基金）高级分析师。担任该职位之前，Edelman从1990年到1994年担任Prudential Securities高级生物技术分析师。Edelman先生的职业生涯始于证券行业的梦百合部门，1987年至1990年在Labe，Simpson担任生物技术分析师。Edelman先生在纽约大学（New York University）获得工商管理硕士学位，并在加利福尼亚大学圣地亚哥分校（University of California San Diego）以优异成绩获得心理学学士学位。
Joseph Edelman serves as the Chairman of Perceptive Capital Solutions Corp's board of directors since March 2024. Mr. Edelman is Founder, Chief Executive Officer and Portfolio Manager of Perceptive Advisors. Mr. Edelman has also served as a director of Athira Pharma, Inc. (Nasdaq: ATHA) since May 2020. He also served as the Chairman of ARYA Sciences Acquisition Corp. from October 2018 to June 2020, ARYA Sciences Acquisition Corp II from July 2020 to October 2020, ARYA Sciences Acquisition Corp III from August 2020 to June 2021, ARYA Sciences Acquisition Corp IV from January 2021 until August 2024, and ARYA Sciences Acquisition Corp V from March 2021 through its liquidation in July 2023. Prior to founding Perceptive Advisors, Mr. Edelman was a Senior Analyst at Aries Fund, a Paramount Capital Asset Management biotechnology hedge fund, from 1994 through 1998. Prior to that position, Mr. Edelman was a Senior Biotechnology Analyst at Prudential Securities from 1990 to 1994. Mr. Edelman started his career in the healthcare sector of the securities industry as a Biotechnology Analyst at Labe, Simpson from 1987 to 1990. Mr. Edelman earned an MBA from New York University and a BA, magna cum laude, in psychology from the University of California San Diego. - Joseph Edelman担任我们的董事会主席。Edelman先生是Perceptive Advisors的创始人，首席执行官和投资组合经理。自2020年7月起，他还担任Arya Sciences Acquisition Corp Iii（Nasdaq:ARYA）的董事会主席。创立Perceptive Advisors之前，Edelman从1994年到1998年担任Aries Fund（Paramount Capital Asset Management生物技术对冲基金）高级分析师。担任该职位之前，Edelman从1990年到1994年担任Prudential Securities高级生物技术分析师。Edelman先生的职业生涯始于证券行业的梦百合部门，1987年至1990年在Labe，Simpson担任生物技术分析师。Edelman先生在纽约大学（New York University）获得工商管理硕士学位，并在加利福尼亚大学圣地亚哥分校（University of California San Diego）以优异成绩获得心理学学士学位。
- Joseph Edelman serves as the Chairman of Perceptive Capital Solutions Corp's board of directors since March 2024. Mr. Edelman is Founder, Chief Executive Officer and Portfolio Manager of Perceptive Advisors. Mr. Edelman has also served as a director of Athira Pharma, Inc. (Nasdaq: ATHA) since May 2020. He also served as the Chairman of ARYA Sciences Acquisition Corp. from October 2018 to June 2020, ARYA Sciences Acquisition Corp II from July 2020 to October 2020, ARYA Sciences Acquisition Corp III from August 2020 to June 2021, ARYA Sciences Acquisition Corp IV from January 2021 until August 2024, and ARYA Sciences Acquisition Corp V from March 2021 through its liquidation in July 2023. Prior to founding Perceptive Advisors, Mr. Edelman was a Senior Analyst at Aries Fund, a Paramount Capital Asset Management biotechnology hedge fund, from 1994 through 1998. Prior to that position, Mr. Edelman was a Senior Biotechnology Analyst at Prudential Securities from 1990 to 1994. Mr. Edelman started his career in the healthcare sector of the securities industry as a Biotechnology Analyst at Labe, Simpson from 1987 to 1990. Mr. Edelman earned an MBA from New York University and a BA, magna cum laude, in psychology from the University of California San Diego.
- Kelly A. Romano
-
KellyA.Romano是BlueRipple Capital，LLC的创始人兼首席执行官，该公司是一家咨询公司，专注于高科技公司和私募股权公司的战略、收购、交易结构和渠道开发。Romano女士于2016年从联合技术公司（United Technologies Corporation）退休，该公司是一家多元化公司，为建筑和航空航天行业提供高技术产品和服务，自1984年起担任多个职责递增的职位。从1993年到2016年，罗曼诺女士在联合技术公司（United Technologies Corporation）担任过多个高级执行职位，包括智能建筑技术，建筑系统与服务总裁（2014年9月至2016年4月），联合技术公司总部企业Vice President，业务发展总裁（2012年3月至2014年9月），全球安全产品总裁，UTC Fire&Security（2011年5月至2012年2月），高级副总裁，全球销售和营销，UTC Fire&Security（2010年1月至2011年4月），Carrier Corporation建筑系统和服务总裁（2006年1月至2009年12月）。Romano女士自2016年12月起担任Gryphon Investors（一家专注于中间市场投资机会的私募股权公司）的执行顾问委员会成员；LLC（一家私募股权公司，专注于对美国工业和制造公司的投资）自2016年5月起担任Xinova，LLC（一家创新开发和银行公司）2016年5月至2020年1月；自2017年12月起担任Potter Electric Signal（领先的喷头监控和消防安全公司）的董事兼董事会联合主席；自2020年8月起担任Start75F的董事，并担任AE Industrial Partners的运营合伙人，LP（一家私募股权公司，专注于航空航天和工业投资）自2020年8月以来。Romano女士目前是DormanProducts，Inc.的董事关于中止《交易法》规定的自愿报告义务，Romano女士还担任UGI Utilities，Inc.的董事至2020年4月。
Kelly A. Romano,is the Chief Executive Officer of BlueRipple Capital, LLC, a consultancy firm she founded in May 2018 that is focused on strategy, acquisitions, deal structure, and channel development for high-technology companies. In addition, she has been an executive advisory board member of Gryphon Investors ("Gryphon"), a private equity firm focused on middle-market investment opportunities, since December 2016, and was Co-Chair of the Board of Potter Electric, one of Gryphon's portfolio companies in the fire life safety industry until November 2023, when it was acquired by KKR & Co. Inc. Ms. Romano served as an operating partner for AE Industrial Partners, LLC, a private equity firm focused in the aerospace and industrial sectors from August 2020 to August 2023. As an operating partner, she served on several of its portfolio company boards. She was the Chair of the Board of Altus Fire & Life Safety from May 2021 until it was sold in August 2024. From 1984 to April 2016, Ms. Romano served in various capacities at United Technologies Corporation ("UTC"), a New York Stock Exchange listed company that provided high-technology products and services to the building and aerospace industries, which merged with Raytheon Corporation in 2020. From September 2014 to April 2016, Ms. Romano served as President, Intelligent Building Technologies for the UTC Building & Industrial Systems business. Previously, she held several other executive-level positions within UTC including President, Global Security Products, President, Building Systems and Services and President, Distribution Americas. Ms. Romano currently serves on the boards of various privately held companies. - KellyA.Romano是BlueRipple Capital，LLC的创始人兼首席执行官，该公司是一家咨询公司，专注于高科技公司和私募股权公司的战略、收购、交易结构和渠道开发。Romano女士于2016年从联合技术公司（United Technologies Corporation）退休，该公司是一家多元化公司，为建筑和航空航天行业提供高技术产品和服务，自1984年起担任多个职责递增的职位。从1993年到2016年，罗曼诺女士在联合技术公司（United Technologies Corporation）担任过多个高级执行职位，包括智能建筑技术，建筑系统与服务总裁（2014年9月至2016年4月），联合技术公司总部企业Vice President，业务发展总裁（2012年3月至2014年9月），全球安全产品总裁，UTC Fire&Security（2011年5月至2012年2月），高级副总裁，全球销售和营销，UTC Fire&Security（2010年1月至2011年4月），Carrier Corporation建筑系统和服务总裁（2006年1月至2009年12月）。Romano女士自2016年12月起担任Gryphon Investors（一家专注于中间市场投资机会的私募股权公司）的执行顾问委员会成员；LLC（一家私募股权公司，专注于对美国工业和制造公司的投资）自2016年5月起担任Xinova，LLC（一家创新开发和银行公司）2016年5月至2020年1月；自2017年12月起担任Potter Electric Signal（领先的喷头监控和消防安全公司）的董事兼董事会联合主席；自2020年8月起担任Start75F的董事，并担任AE Industrial Partners的运营合伙人，LP（一家私募股权公司，专注于航空航天和工业投资）自2020年8月以来。Romano女士目前是DormanProducts，Inc.的董事关于中止《交易法》规定的自愿报告义务，Romano女士还担任UGI Utilities，Inc.的董事至2020年4月。
- Kelly A. Romano,is the Chief Executive Officer of BlueRipple Capital, LLC, a consultancy firm she founded in May 2018 that is focused on strategy, acquisitions, deal structure, and channel development for high-technology companies. In addition, she has been an executive advisory board member of Gryphon Investors ("Gryphon"), a private equity firm focused on middle-market investment opportunities, since December 2016, and was Co-Chair of the Board of Potter Electric, one of Gryphon's portfolio companies in the fire life safety industry until November 2023, when it was acquired by KKR & Co. Inc. Ms. Romano served as an operating partner for AE Industrial Partners, LLC, a private equity firm focused in the aerospace and industrial sectors from August 2020 to August 2023. As an operating partner, she served on several of its portfolio company boards. She was the Chair of the Board of Altus Fire & Life Safety from May 2021 until it was sold in August 2024. From 1984 to April 2016, Ms. Romano served in various capacities at United Technologies Corporation ("UTC"), a New York Stock Exchange listed company that provided high-technology products and services to the building and aerospace industries, which merged with Raytheon Corporation in 2020. From September 2014 to April 2016, Ms. Romano served as President, Intelligent Building Technologies for the UTC Building & Industrial Systems business. Previously, she held several other executive-level positions within UTC including President, Global Security Products, President, Building Systems and Services and President, Distribution Americas. Ms. Romano currently serves on the boards of various privately held companies.
- Mark Litton
-
Mark Litton自2019年7月起担任我们的首席运营官。在加入AthiraPharma，Inc.之前，利顿博士于2018年8月至2019年4月担任上市生物技术公司Alpine ImmuneSciences，Inc.的总裁兼首席运营官。Litton博士曾于2004年至2018年担任上市生物制药公司AlderBiopharmaceuticals，Inc.的首席商务官，财务主管和秘书，该公司由Litton博士于2004年共同创立，于2019年10月被Lundbeck A/S收购。从1999年到2004年，Litton博士担任Celltech Group的业务发展Vice President，在那里他负责许多新发现和治疗计划的安全、商业化和合作。1999年，Litton博士作为ChiroScience Group plc的员工加入Celltech Group，1999年ChiroScience&8217；与Celltech Group合并后被提升为业务发展Vice President。Litton从1997年到1999年担任Ribozyme Pharmaceuticals Inc.（现为Sirna Therapeutics，Inc.）业务开发经理，该公司是一家生物制药公司，也是AlnylamPharmaceuticals，Inc.的全资子公司，他在该公司帮助与礼来公司建立了关系，Roche Bioscience和GlaxoWellcome plc（现为GlaxoSmithKline plc）是一家生物制药公司。Litton从1991年到1994年担任DNAX Research Institute（Schering-Plough（现为Merck&Co.，一家上市制药公司）研究设施）研究助理。Litton博士于1997年在斯德哥尔摩大学（Stockholm University）获得免疫学博士学位，于1994年在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位，并于1990年在加利福尼亚大学圣克鲁斯分校（University of California Santa Cruz）获得生物化学学士学位。
Mark Litton has served as Leonabio, Inc.'s president and chief executive officer and member of Leonabio, Inc.'s board of directors since October 2021 and previously served as Leonabio, Inc.'s chief operating officer from July 2019 to October 2021. Prior to joining Leonabio, Inc., Dr. Litton served as the president and chief operating officer of Alpine Immune Sciences, Inc., a publicly traded biotechnology company, from August 2018 to April 2019. Dr. Litton served as the chief business officer, treasurer, and secretary from 2004 to 2018 of Alder BioPharmaceuticals, Inc., a publicly traded biopharmaceutical company co founded by Dr. Litton in 2004, which was acquired by Lundbeck A/S in October 2019. From 1999 to 2004, Dr. Litton served as vice president of business development for Celltech Group, where he was responsible for securing, commercializing, and partnering on numerous novel discoveries and therapeutic programs. In 1999, Dr. Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to vice president of business development after Chiroscience's merger with Celltech Group in 1999. From 1997 to 1999, Dr. Litton served as the manager of business development for Ribozyme Pharmaceuticals Inc. (now Sirna Therapeutics, Inc.), a biopharmaceutical company and wholly owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc (now GlaxoSmithKline plc) a biopharmaceutical company. From 1991 to 1994, Dr. Litton served as a research associate for DNAX Research Institute, a research facility of Schering Plough (now Merck & Co., a publicly traded pharmaceutical company). Dr. Litton earned a Ph.D. in immunology from Stockholm University in 1997, an M.B.A. from Santa Clara University in 1994 and a B.A. in biochemistry and molecular biology from the University of California Santa Cruz in 1990. - Mark Litton自2019年7月起担任我们的首席运营官。在加入AthiraPharma，Inc.之前，利顿博士于2018年8月至2019年4月担任上市生物技术公司Alpine ImmuneSciences，Inc.的总裁兼首席运营官。Litton博士曾于2004年至2018年担任上市生物制药公司AlderBiopharmaceuticals，Inc.的首席商务官，财务主管和秘书，该公司由Litton博士于2004年共同创立，于2019年10月被Lundbeck A/S收购。从1999年到2004年，Litton博士担任Celltech Group的业务发展Vice President，在那里他负责许多新发现和治疗计划的安全、商业化和合作。1999年，Litton博士作为ChiroScience Group plc的员工加入Celltech Group，1999年ChiroScience&8217；与Celltech Group合并后被提升为业务发展Vice President。Litton从1997年到1999年担任Ribozyme Pharmaceuticals Inc.（现为Sirna Therapeutics，Inc.）业务开发经理，该公司是一家生物制药公司，也是AlnylamPharmaceuticals，Inc.的全资子公司，他在该公司帮助与礼来公司建立了关系，Roche Bioscience和GlaxoWellcome plc（现为GlaxoSmithKline plc）是一家生物制药公司。Litton从1991年到1994年担任DNAX Research Institute（Schering-Plough（现为Merck&Co.，一家上市制药公司）研究设施）研究助理。Litton博士于1997年在斯德哥尔摩大学（Stockholm University）获得免疫学博士学位，于1994年在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位，并于1990年在加利福尼亚大学圣克鲁斯分校（University of California Santa Cruz）获得生物化学学士学位。
- Mark Litton has served as Leonabio, Inc.'s president and chief executive officer and member of Leonabio, Inc.'s board of directors since October 2021 and previously served as Leonabio, Inc.'s chief operating officer from July 2019 to October 2021. Prior to joining Leonabio, Inc., Dr. Litton served as the president and chief operating officer of Alpine Immune Sciences, Inc., a publicly traded biotechnology company, from August 2018 to April 2019. Dr. Litton served as the chief business officer, treasurer, and secretary from 2004 to 2018 of Alder BioPharmaceuticals, Inc., a publicly traded biopharmaceutical company co founded by Dr. Litton in 2004, which was acquired by Lundbeck A/S in October 2019. From 1999 to 2004, Dr. Litton served as vice president of business development for Celltech Group, where he was responsible for securing, commercializing, and partnering on numerous novel discoveries and therapeutic programs. In 1999, Dr. Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to vice president of business development after Chiroscience's merger with Celltech Group in 1999. From 1997 to 1999, Dr. Litton served as the manager of business development for Ribozyme Pharmaceuticals Inc. (now Sirna Therapeutics, Inc.), a biopharmaceutical company and wholly owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc (now GlaxoSmithKline plc) a biopharmaceutical company. From 1991 to 1994, Dr. Litton served as a research associate for DNAX Research Institute, a research facility of Schering Plough (now Merck & Co., a publicly traded pharmaceutical company). Dr. Litton earned a Ph.D. in immunology from Stockholm University in 1997, an M.B.A. from Santa Clara University in 1994 and a B.A. in biochemistry and molecular biology from the University of California Santa Cruz in 1990.
- Barbara Kosacz
-
Barbara Kosacz自2020年7月起担任我们and General Counsel的首席运营官。在加入我们之前，Kosacz女士于1997年1月至2000年12月以及2002年2月至2020年7月再次担任Cooley LLP的合伙人，领导国际生命科学实践。她曾担任生物新兴公司（Bio Emerging Companies）董事会成员、凯克研究院（Keck Graduate Institute）董事会成员、Locust Walk Partners咨询委员会成员，并在多个生命科学相关会议上发表演讲，以及加州大学伯克利分校（University of California，Berkeley）和斯坦福大学（Stanford University）的客座讲师，涉及生物技术法律、生物技术商业模式、企业合作谈判和交易结构以及生物伦理。Kosacz女士自2008年以来被美国最佳律师认可，最近一次被评为2018年生物技术年度律师，她因梦百合被列为A“；领先律师和生命科学作为A&8220；乐队1&221；律师在2018年版《美国商会:美国商业领先律师》中获得2018年法律500强并被IAM Patent1000认可为近三十年来在深度战略和商业水平上为行业内不同公司提供建议并监督其最复杂和最有利可图的交易的律师。Kosacz女士目前是Cooley LLP的高级法律顾问，也是Xoma Corp.（一家上市生物技术公司）的董事会成员。Kosacz女士在斯坦福大学（Stanford University）获得学士学位，并在加州大学伯克利分校法学院（University of California，Berkeley School of Law）获得法学博士学位。
Barbara Kosacz will serve as an independent director immediately upon the effective date of this prospectus. From January 2021 to August 2021 Ms. Kosacz served as a director of LWAC. Since July 2020Ms. Kosacz has served as the Chief Operating Officer and General Counsel of Kronos Bio, Inc. NASDAQ: KRON, a publicly traded clinical-stage biopharmaceutical company. Prior to that, Ms. Kosacz was a Partner at the international law firm of Cooley LLP from January 1997 to December 2000 and again from February 2002 until July 2020 where she led the international Life Sciences Practice. Ms. Kosacz has more than 25 years of experience in counseling clients in the life sciences arena, ranging from early stage startups to larger public companies, venture funds, investment banks, and non-profit institutions. She has served as a member of the BIO Emerging Companies’ Section Governing Board, is a member of the Board of Trustees of the Keck Graduate Institute, an advisory board member of Locust Walk Partners, and has been a speaker at multiple life sciences-related conferences, as well as guest lecturer at the University of California, Berkeley, Columbia University, University of Pennsylvania, and Stanford University about biotechnology law, biotechnology business models, corporate partnering negotiations and deal structures, and bioethics. Recognized by Best Lawyers in America since 2008 and most recently as Biotechnology Lawyer of the Year in 2018 Ms. Kosacz was listed as a “leading lawyer” for healthcare and life sciences in the 2018 Legal 500 as a “Band 1” attorney in the 2018 edition of Chambers USA: America’s Leading Lawyers for Business and recognized as a “highly recommended transactions” lawyer by IAM Patent 1000 for her “nearly three decades advising diverse companies in the industry at a deeply strategic and commercial level and overseeing their most complex and profitable deals.” Ms. Kosacz is currently a member of the board of directors of XOMA Corp. (NASDAQ: XOMA), a royalty aggregation company, and Athira Pharma, Inc. (NASDAQ: ATHA), a late-clinical stage biotechnology company. Ms. Kosacz received her received B.A. from Stanford University and her J.D. from the University of California, Berkeley School of Law. - Barbara Kosacz自2020年7月起担任我们and General Counsel的首席运营官。在加入我们之前，Kosacz女士于1997年1月至2000年12月以及2002年2月至2020年7月再次担任Cooley LLP的合伙人，领导国际生命科学实践。她曾担任生物新兴公司（Bio Emerging Companies）董事会成员、凯克研究院（Keck Graduate Institute）董事会成员、Locust Walk Partners咨询委员会成员，并在多个生命科学相关会议上发表演讲，以及加州大学伯克利分校（University of California，Berkeley）和斯坦福大学（Stanford University）的客座讲师，涉及生物技术法律、生物技术商业模式、企业合作谈判和交易结构以及生物伦理。Kosacz女士自2008年以来被美国最佳律师认可，最近一次被评为2018年生物技术年度律师，她因梦百合被列为A“；领先律师和生命科学作为A&8220；乐队1&221；律师在2018年版《美国商会:美国商业领先律师》中获得2018年法律500强并被IAM Patent1000认可为近三十年来在深度战略和商业水平上为行业内不同公司提供建议并监督其最复杂和最有利可图的交易的律师。Kosacz女士目前是Cooley LLP的高级法律顾问，也是Xoma Corp.（一家上市生物技术公司）的董事会成员。Kosacz女士在斯坦福大学（Stanford University）获得学士学位，并在加州大学伯克利分校法学院（University of California，Berkeley School of Law）获得法学博士学位。
- Barbara Kosacz will serve as an independent director immediately upon the effective date of this prospectus. From January 2021 to August 2021 Ms. Kosacz served as a director of LWAC. Since July 2020Ms. Kosacz has served as the Chief Operating Officer and General Counsel of Kronos Bio, Inc. NASDAQ: KRON, a publicly traded clinical-stage biopharmaceutical company. Prior to that, Ms. Kosacz was a Partner at the international law firm of Cooley LLP from January 1997 to December 2000 and again from February 2002 until July 2020 where she led the international Life Sciences Practice. Ms. Kosacz has more than 25 years of experience in counseling clients in the life sciences arena, ranging from early stage startups to larger public companies, venture funds, investment banks, and non-profit institutions. She has served as a member of the BIO Emerging Companies’ Section Governing Board, is a member of the Board of Trustees of the Keck Graduate Institute, an advisory board member of Locust Walk Partners, and has been a speaker at multiple life sciences-related conferences, as well as guest lecturer at the University of California, Berkeley, Columbia University, University of Pennsylvania, and Stanford University about biotechnology law, biotechnology business models, corporate partnering negotiations and deal structures, and bioethics. Recognized by Best Lawyers in America since 2008 and most recently as Biotechnology Lawyer of the Year in 2018 Ms. Kosacz was listed as a “leading lawyer” for healthcare and life sciences in the 2018 Legal 500 as a “Band 1” attorney in the 2018 edition of Chambers USA: America’s Leading Lawyers for Business and recognized as a “highly recommended transactions” lawyer by IAM Patent 1000 for her “nearly three decades advising diverse companies in the industry at a deeply strategic and commercial level and overseeing their most complex and profitable deals.” Ms. Kosacz is currently a member of the board of directors of XOMA Corp. (NASDAQ: XOMA), a royalty aggregation company, and Athira Pharma, Inc. (NASDAQ: ATHA), a late-clinical stage biotechnology company. Ms. Kosacz received her received B.A. from Stanford University and her J.D. from the University of California, Berkeley School of Law.
- Grant Pickering
-
Grant Pickering自2022年1月起担任Leonabio，Inc.董事会成员。Pickering Co先生自2013年11月起在上市的生物技术公司Vaxcyte, Inc.创立并担任首席执行官和董事会成员。Pickering先生还曾于2013年5月至2015年4月在上市的生物技术公司Atreca, Inc.担任战略顾问。在加入Vaxcyte之前，Pickering先生是Mymetics Corporation的首席执行官，该公司是一家上市的生物技术公司。在此之前，皮克林曾在风险投资公司Kleiner Perkins担任常驻高管，同时在生物制药公司Juvaris BioTherapeutics，Inc.担任首席执行官和董事会成员。在此之前，他曾担任生物技术上市公司Dendreon Corporation的运营高级副总裁。皮克林先生于1997年以优异的成绩获得了乔治敦大学的工商管理硕士学位，并于1989年获得了宾夕法尼亚州立大学的市场营销学士学位。
Grant Pickering has served on Leonabio, Inc.'s board of directors since January 2022. Mr. Pickering co founded and serves as chief executive officer and as a member of the board of directors at Vaxcyte, Inc., a publicly traded biotechnology company, since November 2013. Mr. Pickering also served as strategic advisor at Atreca, Inc., a publicly traded biotechnology company, from May 2013 to April 2015. Prior to joining Vaxcyte, Mr. Pickering was chief executive officer of Mymetics Corporation, a publicly traded biotechnology company. Prior to that, Mr. Pickering served as executive in residence at Kleiner Perkins, a venture capital firm, while serving as the chief executive officer and as a member of the board of directors at Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Prior to that he served as senior vice president of operations of Dendreon Corporation, a publicly traded biotechnology company. Mr. Pickering earned an M.B.A. from Georgetown University in 1997 with high honors and a B.S. in marketing from Penn State University in 1989. - Grant Pickering自2022年1月起担任Leonabio，Inc.董事会成员。Pickering Co先生自2013年11月起在上市的生物技术公司Vaxcyte, Inc.创立并担任首席执行官和董事会成员。Pickering先生还曾于2013年5月至2015年4月在上市的生物技术公司Atreca, Inc.担任战略顾问。在加入Vaxcyte之前，Pickering先生是Mymetics Corporation的首席执行官，该公司是一家上市的生物技术公司。在此之前，皮克林曾在风险投资公司Kleiner Perkins担任常驻高管，同时在生物制药公司Juvaris BioTherapeutics，Inc.担任首席执行官和董事会成员。在此之前，他曾担任生物技术上市公司Dendreon Corporation的运营高级副总裁。皮克林先生于1997年以优异的成绩获得了乔治敦大学的工商管理硕士学位，并于1989年获得了宾夕法尼亚州立大学的市场营销学士学位。
- Grant Pickering has served on Leonabio, Inc.'s board of directors since January 2022. Mr. Pickering co founded and serves as chief executive officer and as a member of the board of directors at Vaxcyte, Inc., a publicly traded biotechnology company, since November 2013. Mr. Pickering also served as strategic advisor at Atreca, Inc., a publicly traded biotechnology company, from May 2013 to April 2015. Prior to joining Vaxcyte, Mr. Pickering was chief executive officer of Mymetics Corporation, a publicly traded biotechnology company. Prior to that, Mr. Pickering served as executive in residence at Kleiner Perkins, a venture capital firm, while serving as the chief executive officer and as a member of the board of directors at Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Prior to that he served as senior vice president of operations of Dendreon Corporation, a publicly traded biotechnology company. Mr. Pickering earned an M.B.A. from Georgetown University in 1997 with high honors and a B.S. in marketing from Penn State University in 1989.
- Kelly A. Romano
-
Kelly A. Romano自2021年8月起担任Leonabio，Inc.董事会主席，自2020年12月起担任Leonabio，Inc.董事会成员。Romano女士在科技公司拥有30多年的高管运营经验，拥有商业建筑和航空航天方面的背景。Romano女士是BlueRipple Capital，LLC的首席执行官，该公司是她于2018年5月创立的一家咨询公司，自2025年8月起担任Grizzly MEP的创始人和董事会主席。Romano女士此前曾于2020年8月至2023年7月在专注于航空航天和工业投资的私募股权公司AEIndustrial Partners担任运营合伙人。Romano女士还曾于2016年12月至2023年11月在中间市场私募股权公司Gryphon Investors的执行顾问委员会任职。此前，她曾在联合技术公司（United Technologies Corp.，简称：UTC）工作了32年，曾担任多个全球高级管理职位，包括UTC建筑与工业系统部门的智能建筑技术总裁以及开利公司的建筑系统与服务部门总裁。Romano女士还是多个董事会成员，包括UGI公司、Dorman Products, Inc.公司和Potter Global Technologies。Romano女士获得了纽约州立大学布法罗分校的工商管理学士学位、雪城大学的工商管理硕士学位，并且毕业于西北大学家乐氏管理学院的公司董事会治理主管课程，以及弗吉尼亚大学达顿管理学院的高级主管课程。
Kelly A. Romano has served as chairwoman of Leonabio, Inc.'s board of directors since August 2021 and as a member of Leonabio, Inc.'s board of directors since December 2020. Ms. Romano brings over 30 years of executive operating experience with technology companies, with a background in commercial buildings and aerospace. Ms. Romano is the chief executive officer of BlueRipple Capital, LLC, a consultancy firm she founded in May 2018 and the founder and chair of the board of directors of Grizzly MEP since August 2025. Ms. Romano previously served as an operating partner at AE Industrial Partners, a private equity firm focused on aerospace and industrial investments, from August 2020 to July 2023. Ms. Romano also served on the Executive Advisory Board at Gryphon Investors, a middle market private equity firm, from December 2016 to November 2023. Previously, she spent 32 years working at United Technologies Corp. (UTC) and held a number of senior executive global positions, including president of Intelligent Building Technologies in UTC Building & Industrial Systems and president of Building Systems & Services at Carrier Corporation. Ms. Romano is also a member of several boards of directors, including UGI Corporation, Dorman Products, Inc., and Potter Global Technologies. Ms. Romano earned a B.S. in business administration from the State University of New York at Buffalo, an M.B.A. from Syracuse University, and is a graduate of the Northwestern University Kellogg School of Management's Corporate Board Governance Executive Program, as well as senior executive programs at Darden School of Management, University of Virginia. - Kelly A. Romano自2021年8月起担任Leonabio，Inc.董事会主席，自2020年12月起担任Leonabio，Inc.董事会成员。Romano女士在科技公司拥有30多年的高管运营经验，拥有商业建筑和航空航天方面的背景。Romano女士是BlueRipple Capital，LLC的首席执行官，该公司是她于2018年5月创立的一家咨询公司，自2025年8月起担任Grizzly MEP的创始人和董事会主席。Romano女士此前曾于2020年8月至2023年7月在专注于航空航天和工业投资的私募股权公司AEIndustrial Partners担任运营合伙人。Romano女士还曾于2016年12月至2023年11月在中间市场私募股权公司Gryphon Investors的执行顾问委员会任职。此前，她曾在联合技术公司（United Technologies Corp.，简称：UTC）工作了32年，曾担任多个全球高级管理职位，包括UTC建筑与工业系统部门的智能建筑技术总裁以及开利公司的建筑系统与服务部门总裁。Romano女士还是多个董事会成员，包括UGI公司、Dorman Products, Inc.公司和Potter Global Technologies。Romano女士获得了纽约州立大学布法罗分校的工商管理学士学位、雪城大学的工商管理硕士学位，并且毕业于西北大学家乐氏管理学院的公司董事会治理主管课程，以及弗吉尼亚大学达顿管理学院的高级主管课程。
- Kelly A. Romano has served as chairwoman of Leonabio, Inc.'s board of directors since August 2021 and as a member of Leonabio, Inc.'s board of directors since December 2020. Ms. Romano brings over 30 years of executive operating experience with technology companies, with a background in commercial buildings and aerospace. Ms. Romano is the chief executive officer of BlueRipple Capital, LLC, a consultancy firm she founded in May 2018 and the founder and chair of the board of directors of Grizzly MEP since August 2025. Ms. Romano previously served as an operating partner at AE Industrial Partners, a private equity firm focused on aerospace and industrial investments, from August 2020 to July 2023. Ms. Romano also served on the Executive Advisory Board at Gryphon Investors, a middle market private equity firm, from December 2016 to November 2023. Previously, she spent 32 years working at United Technologies Corp. (UTC) and held a number of senior executive global positions, including president of Intelligent Building Technologies in UTC Building & Industrial Systems and president of Building Systems & Services at Carrier Corporation. Ms. Romano is also a member of several boards of directors, including UGI Corporation, Dorman Products, Inc., and Potter Global Technologies. Ms. Romano earned a B.S. in business administration from the State University of New York at Buffalo, an M.B.A. from Syracuse University, and is a graduate of the Northwestern University Kellogg School of Management's Corporate Board Governance Executive Program, as well as senior executive programs at Darden School of Management, University of Virginia.
- John M. Fluke, Jr.
-
John M. Fluke, Jr.，是福禄克资本管理有限公司的董事长，一家私人投资公司，并曾担任该职位自1990年以来，他也是临时首席行政人员和CellCyte遗传学公司，生物技术公司的董事，并自2013自2008年起担任该职位。自2011年起担任Pregenen公司是一家生物技术公司，董事长自2011年和Greyrock能源公司自2006年以来超临界技术公司董事兼MicroPlanet技术公司。他此前担任塔利的咖啡公司2005-2011的董事。自1984年起担任公司董事。
John M. Fluke, Jr. has served on Leonabio, Inc.'s board of directors since December 2014. Mr. Fluke is chairman of Fluke Capital Management, L.P., which he founded in 1976, and was chairman and chief executive officer of the John Fluke Manufacturing Co. until 1990. Mr. Fluke previously served on the boards of PACCAR Inc., CellCyte Genetics Corporation, Cell Therapeutics, Primus International, and American Seafoods Group. Mr. Fluke is a current trustee of the Greater Seattle Chamber of Commerce (formerly serving as its chairman), and previously served as chairman of the Washington State China Relations Council and a trustee emeritus of the Museum of Flight. He also previously served as chairman of the Washington Technology Center at the University of Washington, which is an organization responsible for managing technology transfers from public universities in Washington state to the private sector for commercialization. Mr. Fluke has also served as chairman of the trustees of Junior Achievement of Washington and president of the Seattle Council of Boy Scouts of America. Mr. Fluke earned an M.S. in electrical engineering from Stanford University in 1966 and a B.S. in electrical engineering from the University of Washington in 1964. - John M. Fluke, Jr.，是福禄克资本管理有限公司的董事长，一家私人投资公司，并曾担任该职位自1990年以来，他也是临时首席行政人员和CellCyte遗传学公司，生物技术公司的董事，并自2013自2008年起担任该职位。自2011年起担任Pregenen公司是一家生物技术公司，董事长自2011年和Greyrock能源公司自2006年以来超临界技术公司董事兼MicroPlanet技术公司。他此前担任塔利的咖啡公司2005-2011的董事。自1984年起担任公司董事。
- John M. Fluke, Jr. has served on Leonabio, Inc.'s board of directors since December 2014. Mr. Fluke is chairman of Fluke Capital Management, L.P., which he founded in 1976, and was chairman and chief executive officer of the John Fluke Manufacturing Co. until 1990. Mr. Fluke previously served on the boards of PACCAR Inc., CellCyte Genetics Corporation, Cell Therapeutics, Primus International, and American Seafoods Group. Mr. Fluke is a current trustee of the Greater Seattle Chamber of Commerce (formerly serving as its chairman), and previously served as chairman of the Washington State China Relations Council and a trustee emeritus of the Museum of Flight. He also previously served as chairman of the Washington Technology Center at the University of Washington, which is an organization responsible for managing technology transfers from public universities in Washington state to the private sector for commercialization. Mr. Fluke has also served as chairman of the trustees of Junior Achievement of Washington and president of the Seattle Council of Boy Scouts of America. Mr. Fluke earned an M.S. in electrical engineering from Stanford University in 1966 and a B.S. in electrical engineering from the University of Washington in 1964.
- James A. Johnson
-
James A. Johnson自2012年10月担任首席财务官。在加入我公司前，Johnson先生从2011年5月到2012年9月是Relypsa, Inc.的首席财务官，该公司是一家临床阶段的生物制药公司。从2009年9月到2010年10月Johnson先生担任ZymoGenetics, Inc.的真幸福造船厂、首席财务官、财务主管和秘书长，该公司是一家在2010年10月被Bristol-Myers Squibb收购的生物制药公司。Johnson先生从2007年7月到2009年9月担任ZymoGenetics的执行副总裁、首席财务官和财务主管；从2001年2月到2007年7月担任ZymoGenetics的高级副总裁、首席财务官和财务主管。Johnson先生从1994年到2001年2月担任Targeted Genetics Corporation的首席财务官。财务主管和秘书长，该公司是一家生物技术公司；从1999年1月到2001年2月担任负责金融和管理的高级副总裁；从1994年到1999年1月担任负责金融的副总裁。从1990年到1994年，Johnson先生担任Immunex Corporation（一家生物制药公司）负责金融的副总裁；从1988年到1990年担任该公司负责金融的董事。Johnson先生从华盛顿大学（University of Washington）获得工商管理学学士学位。
James A. Johnson has served on Leonabio, Inc.'s board of directors since August 2020. Mr. Johnson previously served as the chief financial officer of Nohla Therapeutics, a cell therapy company, from January 2018 to August 2019. Prior to Nohla, Mr. Johnson served as the chief financial officer of NanoString Technologies, a provider of life science tools for translational research and molecular diagnostics, from October 2012 to December 2017. During his tenure as chief financial officer at NanoString, Mr. Johnson oversaw strategic and corporate finance activities from private stage through the company's initial public offering and additional rounds of financing, marking the third initial public offering in his career as a chief financial officer. Prior to joining NanoString, Mr. Johnson served as chief financial officer of Relypsa, Inc., a clinical stage biopharmaceutical company. Prior to Relypsa, Mr. Johnson served for nearly 10 years as chief financial officer of ZymoGenetics, Inc., until the company was acquired by Bristol Myers Squibb in October 2010. Previously, he served for seven years as chief financial officer of Targeted Genetics Corporation (renamed Armata Pharmaceuticals) and as Vice President of Finance at Immunex Corporation during its evolution from product development to commercial operations. Mr. Johnson received a B.A. in business administration from the University of Washington in 1979. - James A. Johnson自2012年10月担任首席财务官。在加入我公司前，Johnson先生从2011年5月到2012年9月是Relypsa, Inc.的首席财务官，该公司是一家临床阶段的生物制药公司。从2009年9月到2010年10月Johnson先生担任ZymoGenetics, Inc.的真幸福造船厂、首席财务官、财务主管和秘书长，该公司是一家在2010年10月被Bristol-Myers Squibb收购的生物制药公司。Johnson先生从2007年7月到2009年9月担任ZymoGenetics的执行副总裁、首席财务官和财务主管；从2001年2月到2007年7月担任ZymoGenetics的高级副总裁、首席财务官和财务主管。Johnson先生从1994年到2001年2月担任Targeted Genetics Corporation的首席财务官。财务主管和秘书长，该公司是一家生物技术公司；从1999年1月到2001年2月担任负责金融和管理的高级副总裁；从1994年到1999年1月担任负责金融的副总裁。从1990年到1994年，Johnson先生担任Immunex Corporation（一家生物制药公司）负责金融的副总裁；从1988年到1990年担任该公司负责金融的董事。Johnson先生从华盛顿大学（University of Washington）获得工商管理学学士学位。
- James A. Johnson has served on Leonabio, Inc.'s board of directors since August 2020. Mr. Johnson previously served as the chief financial officer of Nohla Therapeutics, a cell therapy company, from January 2018 to August 2019. Prior to Nohla, Mr. Johnson served as the chief financial officer of NanoString Technologies, a provider of life science tools for translational research and molecular diagnostics, from October 2012 to December 2017. During his tenure as chief financial officer at NanoString, Mr. Johnson oversaw strategic and corporate finance activities from private stage through the company's initial public offering and additional rounds of financing, marking the third initial public offering in his career as a chief financial officer. Prior to joining NanoString, Mr. Johnson served as chief financial officer of Relypsa, Inc., a clinical stage biopharmaceutical company. Prior to Relypsa, Mr. Johnson served for nearly 10 years as chief financial officer of ZymoGenetics, Inc., until the company was acquired by Bristol Myers Squibb in October 2010. Previously, he served for seven years as chief financial officer of Targeted Genetics Corporation (renamed Armata Pharmaceuticals) and as Vice President of Finance at Immunex Corporation during its evolution from product development to commercial operations. Mr. Johnson received a B.A. in business administration from the University of Washington in 1979.
高管简历
中英对照 | 中文 | 英文- Mark Litton
Mark Litton自2019年7月起担任我们的首席运营官。在加入AthiraPharma，Inc.之前，利顿博士于2018年8月至2019年4月担任上市生物技术公司Alpine ImmuneSciences，Inc.的总裁兼首席运营官。Litton博士曾于2004年至2018年担任上市生物制药公司AlderBiopharmaceuticals，Inc.的首席商务官，财务主管和秘书，该公司由Litton博士于2004年共同创立，于2019年10月被Lundbeck A/S收购。从1999年到2004年，Litton博士担任Celltech Group的业务发展Vice President，在那里他负责许多新发现和治疗计划的安全、商业化和合作。1999年，Litton博士作为ChiroScience Group plc的员工加入Celltech Group，1999年ChiroScience&8217；与Celltech Group合并后被提升为业务发展Vice President。Litton从1997年到1999年担任Ribozyme Pharmaceuticals Inc.（现为Sirna Therapeutics，Inc.）业务开发经理，该公司是一家生物制药公司，也是AlnylamPharmaceuticals，Inc.的全资子公司，他在该公司帮助与礼来公司建立了关系，Roche Bioscience和GlaxoWellcome plc（现为GlaxoSmithKline plc）是一家生物制药公司。Litton从1991年到1994年担任DNAX Research Institute（Schering-Plough（现为Merck&Co.，一家上市制药公司）研究设施）研究助理。Litton博士于1997年在斯德哥尔摩大学（Stockholm University）获得免疫学博士学位，于1994年在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位，并于1990年在加利福尼亚大学圣克鲁斯分校（University of California Santa Cruz）获得生物化学学士学位。
Mark Litton has served as Leonabio, Inc.'s president and chief executive officer and member of Leonabio, Inc.'s board of directors since October 2021 and previously served as Leonabio, Inc.'s chief operating officer from July 2019 to October 2021. Prior to joining Leonabio, Inc., Dr. Litton served as the president and chief operating officer of Alpine Immune Sciences, Inc., a publicly traded biotechnology company, from August 2018 to April 2019. Dr. Litton served as the chief business officer, treasurer, and secretary from 2004 to 2018 of Alder BioPharmaceuticals, Inc., a publicly traded biopharmaceutical company co founded by Dr. Litton in 2004, which was acquired by Lundbeck A/S in October 2019. From 1999 to 2004, Dr. Litton served as vice president of business development for Celltech Group, where he was responsible for securing, commercializing, and partnering on numerous novel discoveries and therapeutic programs. In 1999, Dr. Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to vice president of business development after Chiroscience's merger with Celltech Group in 1999. From 1997 to 1999, Dr. Litton served as the manager of business development for Ribozyme Pharmaceuticals Inc. (now Sirna Therapeutics, Inc.), a biopharmaceutical company and wholly owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc (now GlaxoSmithKline plc) a biopharmaceutical company. From 1991 to 1994, Dr. Litton served as a research associate for DNAX Research Institute, a research facility of Schering Plough (now Merck & Co., a publicly traded pharmaceutical company). Dr. Litton earned a Ph.D. in immunology from Stockholm University in 1997, an M.B.A. from Santa Clara University in 1994 and a B.A. in biochemistry and molecular biology from the University of California Santa Cruz in 1990.- Mark Litton自2019年7月起担任我们的首席运营官。在加入AthiraPharma，Inc.之前，利顿博士于2018年8月至2019年4月担任上市生物技术公司Alpine ImmuneSciences，Inc.的总裁兼首席运营官。Litton博士曾于2004年至2018年担任上市生物制药公司AlderBiopharmaceuticals，Inc.的首席商务官，财务主管和秘书，该公司由Litton博士于2004年共同创立，于2019年10月被Lundbeck A/S收购。从1999年到2004年，Litton博士担任Celltech Group的业务发展Vice President，在那里他负责许多新发现和治疗计划的安全、商业化和合作。1999年，Litton博士作为ChiroScience Group plc的员工加入Celltech Group，1999年ChiroScience&8217；与Celltech Group合并后被提升为业务发展Vice President。Litton从1997年到1999年担任Ribozyme Pharmaceuticals Inc.（现为Sirna Therapeutics，Inc.）业务开发经理，该公司是一家生物制药公司，也是AlnylamPharmaceuticals，Inc.的全资子公司，他在该公司帮助与礼来公司建立了关系，Roche Bioscience和GlaxoWellcome plc（现为GlaxoSmithKline plc）是一家生物制药公司。Litton从1991年到1994年担任DNAX Research Institute（Schering-Plough（现为Merck&Co.，一家上市制药公司）研究设施）研究助理。Litton博士于1997年在斯德哥尔摩大学（Stockholm University）获得免疫学博士学位，于1994年在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位，并于1990年在加利福尼亚大学圣克鲁斯分校（University of California Santa Cruz）获得生物化学学士学位。
- Mark Litton has served as Leonabio, Inc.'s president and chief executive officer and member of Leonabio, Inc.'s board of directors since October 2021 and previously served as Leonabio, Inc.'s chief operating officer from July 2019 to October 2021. Prior to joining Leonabio, Inc., Dr. Litton served as the president and chief operating officer of Alpine Immune Sciences, Inc., a publicly traded biotechnology company, from August 2018 to April 2019. Dr. Litton served as the chief business officer, treasurer, and secretary from 2004 to 2018 of Alder BioPharmaceuticals, Inc., a publicly traded biopharmaceutical company co founded by Dr. Litton in 2004, which was acquired by Lundbeck A/S in October 2019. From 1999 to 2004, Dr. Litton served as vice president of business development for Celltech Group, where he was responsible for securing, commercializing, and partnering on numerous novel discoveries and therapeutic programs. In 1999, Dr. Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to vice president of business development after Chiroscience's merger with Celltech Group in 1999. From 1997 to 1999, Dr. Litton served as the manager of business development for Ribozyme Pharmaceuticals Inc. (now Sirna Therapeutics, Inc.), a biopharmaceutical company and wholly owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc (now GlaxoSmithKline plc) a biopharmaceutical company. From 1991 to 1994, Dr. Litton served as a research associate for DNAX Research Institute, a research facility of Schering Plough (now Merck & Co., a publicly traded pharmaceutical company). Dr. Litton earned a Ph.D. in immunology from Stockholm University in 1997, an M.B.A. from Santa Clara University in 1994 and a B.A. in biochemistry and molecular biology from the University of California Santa Cruz in 1990.
- Kevin Church
凯文·丘奇（Kevin Church）自2016年以来一直在阿提拉担任多个职位，包括研究科学家，探索总监，现为探索Vice President。Church博士于2016年在华盛顿州立大学（Washington State University）获得分子生物学博士学位，在此之前于2006年在爱达荷大学（University of Idaho）获得微生物学学士学位。在研究生院期间，Church博士因其研究生教学助学金的卓越表现而获得认可。Church博士的研究生工作主要专注于开发用于治疗胰腺癌的新型疗法，但也包括与糖尿病溃疡和神经退行性疾病（例如帕金森氏病痴呆和阿尔茨海默病）的治疗有关的研究。
Kevin Church has served as Leonabio, Inc.'s chief scientific officer since January 2023. Prior to this, Dr. Church held various roles at the Company, including executive vice president of research from October 2021 to January 2023, vice president of discovery from July 2020 to October 2021, director of discovery from July 2018 to July 2020, senior research scientist from February 2018 to July 2018, and research scientist from July 2016 to February 2018. Dr. Church has research experience in diverse fields of study including neurodegenerative diseases, wound healing, and cancer. Dr. Church earned his Ph.D. in molecular biosciences from Washington State University in 2016, and prior to that earned his B.S. in microbiology from the University of Idaho in 2006. While in graduate school, Dr. Church was recognized for excellence in his graduate teaching assistantships. Dr. Church's graduate work primarily focused on the development of novel therapeutics for the treatment of pancreatic cancer, but also included research relating to the treatment of diabetic ulcers and neurodegenerative diseases such as Parkinson's disease dementia and Alzheimer's disease.- 凯文·丘奇（Kevin Church）自2016年以来一直在阿提拉担任多个职位，包括研究科学家，探索总监，现为探索Vice President。Church博士于2016年在华盛顿州立大学（Washington State University）获得分子生物学博士学位，在此之前于2006年在爱达荷大学（University of Idaho）获得微生物学学士学位。在研究生院期间，Church博士因其研究生教学助学金的卓越表现而获得认可。Church博士的研究生工作主要专注于开发用于治疗胰腺癌的新型疗法，但也包括与糖尿病溃疡和神经退行性疾病（例如帕金森氏病痴呆和阿尔茨海默病）的治疗有关的研究。
- Kevin Church has served as Leonabio, Inc.'s chief scientific officer since January 2023. Prior to this, Dr. Church held various roles at the Company, including executive vice president of research from October 2021 to January 2023, vice president of discovery from July 2020 to October 2021, director of discovery from July 2018 to July 2020, senior research scientist from February 2018 to July 2018, and research scientist from July 2016 to February 2018. Dr. Church has research experience in diverse fields of study including neurodegenerative diseases, wound healing, and cancer. Dr. Church earned his Ph.D. in molecular biosciences from Washington State University in 2016, and prior to that earned his B.S. in microbiology from the University of Idaho in 2006. While in graduate school, Dr. Church was recognized for excellence in his graduate teaching assistantships. Dr. Church's graduate work primarily focused on the development of novel therapeutics for the treatment of pancreatic cancer, but also included research relating to the treatment of diabetic ulcers and neurodegenerative diseases such as Parkinson's disease dementia and Alzheimer's disease.
- Javier San Martin
Javier San Martin，首席医疗官，于2019年11月加入公司。San Martin博士曾于2013年至2019年11月担任Ultragenyx的高级副总裁兼全球临床开发主管。在Ultragenyx，他领导了Burosumab（一种治疗X连锁低磷血症的新药，在包括美国、欧盟和加拿大在内的主要地区获得批准）的开发。任职Ultragenyx公司之前，他曾担任Alder Biopharmaceuticals公司的临床开发高级副总裁，在那里他负责管理专注于早期临床项目的医疗、监管和临床运营集团。从2006年到2011年，他曾担任Amgen公司的全球开发领导，在那里他曾负责两个主要开发计划。他指导the Romosozumab Clinical Program直到II期结束，在此之前，负责DeNosumab的开发和批准，DeNosumab是最大的品牌抗骨质疏松治疗绝经后骨质疏松症的药物，也是第一个针对初级保健医生治疗的非常流行的疾病的单克隆抗体。任职Amgen公司之前，他曾任职礼来公司公司7年，支持后期临床开发和医疗事务活动，包括Evista公司和Forteo公司的成功上市。他在布宜诺斯艾利斯大学医学院（University of Buenos Aires Medical School）获得医学学位，并在阿根廷布宜诺斯艾利斯CEMC University Hospital完成内科住院，担任首席住院医师，此后担任主治医师，负责内科病房。
Javier San Martin,Chief Medical Officer, joined the Company in November 2019. Dr. San Martin previously served as Senior Vice President and Head of Global Clinical Development at Ultragenyx from 2013 until November 2019. At Ultragenyx he led the development of burosumab, a novel drug for the treatment of X-Linked Hypophosphatemia approved across major regions including the United States, the European Union, and Canada. Before his tenure at Ultragenyx, he served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals, where he was responsible for managing the medical, regulatory, and clinical operations group focused on early clinical programs. From 2006 to 2011, Dr. San Martin was a Global Development Leader at Amgen, Inc., where he was responsible for two major development programs. He directed the romosozumab clinical program through the end of phase II, and before that, was responsible for the development and approval of denosumab, the largest branded anti-osteoporosis treatment for postmenopausal osteoporosis and the first monoclonal antibody to address a very prevalent disease treated by primary care physicians. Prior to his time at Amgen, he spent seven years at Eli Lilly and Company, supporting late stage clinical development as well as medical affairs activities, including the successful launch of Evista and Forteo. He received his medical degree from the University of Buenos Aires Medical School and completed his residence in internal medicine at CEMIC University Hospital in Buenos Aires, Argentina, serving as Chief Resident, and, thereafter, as Attending Physician responsible for the internal medicine ward.- Javier San Martin，首席医疗官，于2019年11月加入公司。San Martin博士曾于2013年至2019年11月担任Ultragenyx的高级副总裁兼全球临床开发主管。在Ultragenyx，他领导了Burosumab（一种治疗X连锁低磷血症的新药，在包括美国、欧盟和加拿大在内的主要地区获得批准）的开发。任职Ultragenyx公司之前，他曾担任Alder Biopharmaceuticals公司的临床开发高级副总裁，在那里他负责管理专注于早期临床项目的医疗、监管和临床运营集团。从2006年到2011年，他曾担任Amgen公司的全球开发领导，在那里他曾负责两个主要开发计划。他指导the Romosozumab Clinical Program直到II期结束，在此之前，负责DeNosumab的开发和批准，DeNosumab是最大的品牌抗骨质疏松治疗绝经后骨质疏松症的药物，也是第一个针对初级保健医生治疗的非常流行的疾病的单克隆抗体。任职Amgen公司之前，他曾任职礼来公司公司7年，支持后期临床开发和医疗事务活动，包括Evista公司和Forteo公司的成功上市。他在布宜诺斯艾利斯大学医学院（University of Buenos Aires Medical School）获得医学学位，并在阿根廷布宜诺斯艾利斯CEMC University Hospital完成内科住院，担任首席住院医师，此后担任主治医师，负责内科病房。
- Javier San Martin,Chief Medical Officer, joined the Company in November 2019. Dr. San Martin previously served as Senior Vice President and Head of Global Clinical Development at Ultragenyx from 2013 until November 2019. At Ultragenyx he led the development of burosumab, a novel drug for the treatment of X-Linked Hypophosphatemia approved across major regions including the United States, the European Union, and Canada. Before his tenure at Ultragenyx, he served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals, where he was responsible for managing the medical, regulatory, and clinical operations group focused on early clinical programs. From 2006 to 2011, Dr. San Martin was a Global Development Leader at Amgen, Inc., where he was responsible for two major development programs. He directed the romosozumab clinical program through the end of phase II, and before that, was responsible for the development and approval of denosumab, the largest branded anti-osteoporosis treatment for postmenopausal osteoporosis and the first monoclonal antibody to address a very prevalent disease treated by primary care physicians. Prior to his time at Amgen, he spent seven years at Eli Lilly and Company, supporting late stage clinical development as well as medical affairs activities, including the successful launch of Evista and Forteo. He received his medical degree from the University of Buenos Aires Medical School and completed his residence in internal medicine at CEMIC University Hospital in Buenos Aires, Argentina, serving as Chief Resident, and, thereafter, as Attending Physician responsible for the internal medicine ward.
- Mark Worthington
Mark Worthington自2021年6月起担任Leonabio，Inc.的总法律顾问，此前他曾在Leonabio，Inc.担任外部公司法律顾问数年。在加入公司之前，Worthington先生于1997年9月至2021年5月期间担任华盛顿州西雅图Summit Law Group的合伙人，在那里从事公司和证券法业务，主持公司/证券业务并担任共同管理合伙人。沃辛顿先生曾就广泛的公司治理、合规和交易事项（包括公开发行、并购和合资企业）为私营和公共生命科学公司及其他公司提供咨询，并与执行管理团队就战略业务和法律事项密切合作。沃辛顿先生于1993年在旧金山加州大学法学院获得法学博士学位，并于1988年在斯坦福大学获得美国研究学士学位。
Mark Worthington has served as Leonabio, Inc.'s general counsel since June 2021, after working with Leonabio, Inc. as outside corporate counsel for several years. Prior to joining the Company, Mr. Worthington served as a partner with Summit Law Group in Seattle, Washington from September 1997 to May 2021, where he practiced corporate and securities law, chaired the corporate/securities practice and served as the co managing partner. Mr. Worthington has advised private and public life sciences and other companies on a wide range of corporate governance, compliance and transactional matters, including public offerings, mergers and acquisitions, and joint ventures, and worked closely with executive management teams on strategic business and legal matters. Mr. Worthington received his J.D. from University of California College of the Law, San Francisco, in 1993 and his B.A. in American Studies from Stanford University in 1988.- Mark Worthington自2021年6月起担任Leonabio，Inc.的总法律顾问，此前他曾在Leonabio，Inc.担任外部公司法律顾问数年。在加入公司之前，Worthington先生于1997年9月至2021年5月期间担任华盛顿州西雅图Summit Law Group的合伙人，在那里从事公司和证券法业务，主持公司/证券业务并担任共同管理合伙人。沃辛顿先生曾就广泛的公司治理、合规和交易事项（包括公开发行、并购和合资企业）为私营和公共生命科学公司及其他公司提供咨询，并与执行管理团队就战略业务和法律事项密切合作。沃辛顿先生于1993年在旧金山加州大学法学院获得法学博士学位，并于1988年在斯坦福大学获得美国研究学士学位。
- Mark Worthington has served as Leonabio, Inc.'s general counsel since June 2021, after working with Leonabio, Inc. as outside corporate counsel for several years. Prior to joining the Company, Mr. Worthington served as a partner with Summit Law Group in Seattle, Washington from September 1997 to May 2021, where he practiced corporate and securities law, chaired the corporate/securities practice and served as the co managing partner. Mr. Worthington has advised private and public life sciences and other companies on a wide range of corporate governance, compliance and transactional matters, including public offerings, mergers and acquisitions, and joint ventures, and worked closely with executive management teams on strategic business and legal matters. Mr. Worthington received his J.D. from University of California College of the Law, San Francisco, in 1993 and his B.A. in American Studies from Stanford University in 1988.
- Robert Renninger
- 暂无中文简介
Robert Renninger has served as Leonabio, Inc.'s Chief Financial Officer since December 2025. From February 2025 to December 2025, he served as senior vice president, finance and accounting, and previously served as Leonabio, Inc.'s vice president of finance from January 2022 to February 2025, as Leonabio, Inc.'s senior director of finance from September 2020 to January 2022, and as Leonabio, Inc.'s director of finance from July 2020 to September 2020. Mr. Renninger served as financial controller of Infobip (formerly OpenMarket), a global communications platform, from July 2019 to July 2020. He also served as technical controller of Baker Hughes, an energy company, from September 2017 to May 2019. Mr. Renninger also served in various roles at Ernst & Young, LLP, a global accounting firm, from September 2007 through September 2017, including most recently as senior manager. Mr. Renninger received his Master of accounting from the University of Michigan in 2007 and his B.A. in accounting from Seattle University in 2006. Mr. Renninger has over 15 years of experience serving in various finance, accounting, and auditing positions for companies in the pharmaceutical, technology, and energy sectors. - 暂无中文简介
- Robert Renninger has served as Leonabio, Inc.'s Chief Financial Officer since December 2025. From February 2025 to December 2025, he served as senior vice president, finance and accounting, and previously served as Leonabio, Inc.'s vice president of finance from January 2022 to February 2025, as Leonabio, Inc.'s senior director of finance from September 2020 to January 2022, and as Leonabio, Inc.'s director of finance from July 2020 to September 2020. Mr. Renninger served as financial controller of Infobip (formerly OpenMarket), a global communications platform, from July 2019 to July 2020. He also served as technical controller of Baker Hughes, an energy company, from September 2017 to May 2019. Mr. Renninger also served in various roles at Ernst & Young, LLP, a global accounting firm, from September 2007 through September 2017, including most recently as senior manager. Mr. Renninger received his Master of accounting from the University of Michigan in 2007 and his B.A. in accounting from Seattle University in 2006. Mr. Renninger has over 15 years of experience serving in various finance, accounting, and auditing positions for companies in the pharmaceutical, technology, and energy sectors.
- Robert Renninger
Robert Renninger自2025年12月起担任Leonabio，Inc.的首席财务官。2025年2月至2025年12月任财务和会计部高级副总裁，此前于2022年1月至2025年2月任Leonabio，Inc.财务副总裁，于2020年9月至2022年1月任Leonabio，Inc.财务高级总监，于2020年7月至2020年9月任Leonabio，Inc.财务总监。Renninger先生曾于2019年7月至2020年7月担任全球通信平台Infobip（前身为OpenMarket）的财务总监。他还曾于2017年9月至2019年5月担任能源公司Baker Hughes的技术总监。Renninger先生还曾于2007年9月至2017年9月在全球会计师事务所Ernst & Young，LLP担任过各种职务，包括最近担任高级经理。Renninger先生于2007年获得密歇根大学会计学硕士学位，并于2006年获得西雅图大学会计学学士学位。Renninger先生在制药、技术和能源领域的公司担任各种财务、会计和审计职位方面拥有超过15年的经验。
Robert Renninger has served as Leonabio, Inc.'s Chief Financial Officer since December 2025. From February 2025 to December 2025, he served as senior vice president, finance and accounting, and previously served as Leonabio, Inc.'s vice president of finance from January 2022 to February 2025, as Leonabio, Inc.'s senior director of finance from September 2020 to January 2022, and as Leonabio, Inc.'s director of finance from July 2020 to September 2020. Mr. Renninger served as financial controller of Infobip (formerly OpenMarket), a global communications platform, from July 2019 to July 2020. He also served as technical controller of Baker Hughes, an energy company, from September 2017 to May 2019. Mr. Renninger also served in various roles at Ernst & Young, LLP, a global accounting firm, from September 2007 through September 2017, including most recently as senior manager. Mr. Renninger received his Master of accounting from the University of Michigan in 2007 and his B.A. in accounting from Seattle University in 2006. Mr. Renninger has over 15 years of experience serving in various finance, accounting, and auditing positions for companies in the pharmaceutical, technology, and energy sectors.- Robert Renninger自2025年12月起担任Leonabio，Inc.的首席财务官。2025年2月至2025年12月任财务和会计部高级副总裁，此前于2022年1月至2025年2月任Leonabio，Inc.财务副总裁，于2020年9月至2022年1月任Leonabio，Inc.财务高级总监，于2020年7月至2020年9月任Leonabio，Inc.财务总监。Renninger先生曾于2019年7月至2020年7月担任全球通信平台Infobip（前身为OpenMarket）的财务总监。他还曾于2017年9月至2019年5月担任能源公司Baker Hughes的技术总监。Renninger先生还曾于2007年9月至2017年9月在全球会计师事务所Ernst & Young，LLP担任过各种职务，包括最近担任高级经理。Renninger先生于2007年获得密歇根大学会计学硕士学位，并于2006年获得西雅图大学会计学学士学位。Renninger先生在制药、技术和能源领域的公司担任各种财务、会计和审计职位方面拥有超过15年的经验。
- Robert Renninger has served as Leonabio, Inc.'s Chief Financial Officer since December 2025. From February 2025 to December 2025, he served as senior vice president, finance and accounting, and previously served as Leonabio, Inc.'s vice president of finance from January 2022 to February 2025, as Leonabio, Inc.'s senior director of finance from September 2020 to January 2022, and as Leonabio, Inc.'s director of finance from July 2020 to September 2020. Mr. Renninger served as financial controller of Infobip (formerly OpenMarket), a global communications platform, from July 2019 to July 2020. He also served as technical controller of Baker Hughes, an energy company, from September 2017 to May 2019. Mr. Renninger also served in various roles at Ernst & Young, LLP, a global accounting firm, from September 2007 through September 2017, including most recently as senior manager. Mr. Renninger received his Master of accounting from the University of Michigan in 2007 and his B.A. in accounting from Seattle University in 2006. Mr. Renninger has over 15 years of experience serving in various finance, accounting, and auditing positions for companies in the pharmaceutical, technology, and energy sectors.